Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-08-16

Clinical Trial Update: Empa/Lina FDC Food Effect Study (Japan) [Phase 1]

View source ↗

Summary

Phase 1 food effect study of Empagliflozin/Linagliptin fixed-dose combination conducted in Japan has completed; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Empagliflozin / Linagliptin fixed-dose combination (empagliflozin/linagliptin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Healthy | Phase 1 | Status: COMPLETED | Results posted: 2018-08-16